Herbal medicines have gained growing popularity and wide usage in the world in the last twenty years. As estimated by the World Health Organization, 80% of people worldwide rely on herbal medicines for part of their primary health care needs[@b1]. In China, roughly 1000 herbs are available and are prescribed by TCM practitioners or produced as herbal preparations by pharmaceutical manufacturers[@b2]. In the United States, an interest in returning to natural or organic remedies has led to an increase in herbal medicines use[@b3].

Establishing the evidence-based pharmacokinetics and pharmacodynamics for efficacy of herbal medicines is a constant challenge[@b4]. Of particular interest is characterization of the complex chemical compositions in herbal medicines. Next of interest are the identification of absorbed compounds and metabolites after oral administration of herbal medicines. Of further interest are the elucidation of metabolic pathways, and the assessment of elimination routes and their kinetics[@b5][@b6][@b7].These data become an important issue to link data from pharmacological assays and clinical effects. A better understanding of the pharmacokinetics of phytopharmaceuticals can also help in predicting potential herb-drug interactions and designing rational dosage regimens.

However, pharmacokinetic studies on herbal medicines are very difficult to investigate because of their chemical complexity[@b8]. As a result, there is very little pharmacokinetic data for many herbal products that are commonly used in clinics and hospitals[@b9]. In most cases, researchers tend to test the pharmacokinetics of a single compound isolated from an extract using *in vitro* and *in vivo* models[@b10]. Because of competitive or synergistic absorption and metabolism among various components, differences can be observed between the administration of a single compound and of a compound-contained herbal extract[@b11].

A great number of scientists have contributed to developing various methods for analyzing the herbal samples and herbal-treated biological samples[@b12][@b13]. Advances in sample pretreatment and analytical technology have improved analysis time, sensitivity and efficiency[@b14][@b15]. An emerging instrument trend has been the application of liquid chromatography combined with mass spectrometry (LC-MS) to online structural characterization and quantification[@b16]. MS includes quadruple (Q)-MS, ion trap (IT)-MS, time-of-flight (TOF)-MS instruments, and more recently, Q-IT, IT-TOF and Q-TOF[@b17][@b18].

K-601 is a hospital-prepared medicinal formulation comprising five herbs, i.e., *Lonicera japonica* Thunb., *Isatis indigotica* Fort., *Rheum palmatum* L., *Phellodendron chinense* Schneid., and *Scutellaria baicalensis* Georgi. It is used in clinic for the alleviation of the symptoms of influenza and treatment of cough due to non-bacterial causes. It is very popular for use in both children and adults in China. Analyses of individual compounds and herbs within this formulation have been studied in terms of chemical composition, quantification, *in vitro* and *in vivo* analysis[@b19][@b20]. However, no pharmacokinetic studies have been conducted on the unique formulation of K-601 in humans. The aim of this work was to investigate the pharmacokinetics of K-601 in humans by ultra-performance (UP) LC-QTOF/MS, and develop a universal strategy for similar studies of other herbal products. We characterized the chemical constituents in K-601 by a diagnostic-ion screening method, identified the absorbed prototype compounds and their metabolites in healthy Chinese and African volunteers by compound-metabolite matching approach, and determined the pharmacokinetics of some bioactive components. The UPLC-QTOF/MS provided superior data quality and advanced analytical capabilities for profiling, identifying, and determining complex constituents and metabolites in matrix-based biological samples.

Results
=======

A strategy proposed to investigate pharmacokinetics of multicomponent herbal preparations
-----------------------------------------------------------------------------------------

A strategy was schemed ([Fig. 1](#f1){ref-type="fig"}) to investigate pharmacokinetics of multicomponent herbal preparations. The whole process consists of four steps: (a) chemical profile and structural assignment based on diagnostic ions by LC-MS; (b) LC-MS analysis of biological samples after herbal treatment on humans with different races, ages and volunteers/patients; (c) identification of parent compounds and metabolites in biosamples by data matching; (d) pharmacokinetic studies of high abundant markers in biosamples. Pharmacokinetic studies should be associated with pharmacological effects and clinical efficacy. The results benefit discovery of potential bioactive combinational components and prediction of possible herb-drug interactions.

Batch to batch quality evaluation of K-601 formulation
------------------------------------------------------

To assess the batch to batch consistency of K-601, a simple UPLC method was developed. Fingerprint analysis was conducted on these chromatograms using the software, *Similarity Evaluation System for Chromatographic Fingerprint of TCM, 2004* ([Fig. 2](#f2){ref-type="fig"}). Upon aligning all the peaks, the reference chromatogram was generated by reserving peaks above 0.1% of the percentage area. Peaks that existed in all chromatograms of the samples with reasonable heights and good resolutions were assigned as "common peaks". The total area of the common peaks must be more than 90% of the peak area of the whole chromatogram. Similarity was reported in terms of cosine ratios ([Supplementary Table S1](#S1){ref-type="supplementary-material"}). The results indicated high similarities among the nine batches of K-601 with values higher than 0.983.

Identification of chemical constituents in formulation
------------------------------------------------------

Assignment of peaks in chemical profile of herbal products is challenging, since most of reference compounds are unavailable for structural confirmation. A diagnostic-ion screening strategy was proposed. Briefly, the diagnostic ions corresponding to a mother skeleton obtained from reference compounds are used to screen the same type of compounds[@b5][@b21]. Then, the molecular ions of screened peaks were calculated using both negative and positive ion modes. Next, the accurate molecular formula of each peak obtained was applied to screening for a hit against various chemical databases. A most possible structure that contains such a substructure and substituent groups can be determined from these candidates by comparison of characteristic product ions and fragmentation pathways. Some peaks were further confirmed using reference compounds. With the diagnostic ions strategy, 50 compounds were identified in K-601 sample by UPLC-QTOF/MS. The total ion chromatograms (TICs) of the extract in negative and positive ion modes were presented ([Fig. 3A,B](#f3){ref-type="fig"}). The retention times, MS data and peak height abundance of the characterized compounds were summarized ([Table 1](#t1){ref-type="table"}). The herbal sources for each peak were also included. All the structures of the compounds identified in K-601 were summarized in [Supplementary Figure S1](#S1){ref-type="supplementary-material"}.

Identification of herbal constituents and their metabolites in human plasma
---------------------------------------------------------------------------

The detection and identification of chemical compositions in biosamples including prototype compounds and metabolites is a crucial step to uncover the pharmacologically active substances of herbal medicines[@b22]. Biological metabolic networks of complex mixtures were characterized by procedures of (a) mass data collection, (b) endogenous interference subtraction, (c) matching the mass differences of pseudomolecular ions between the metabolites and parent compounds based on typical metabolic pathways, (d) confirming the absorbed compounds by MS/MS product ions.

A total of 15 prototype compounds and 17 metabolites were identified. These identified metabolites were selected based on their peak abundances and intensities. Their MS data and peak height abundances of the characterized compounds were summarized ([Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}).

Pharmacokinetics
----------------

The pharmacokinetics of the four major compounds, i.e., berberine, jatrorrhizine, palmatine, and magnoflorine were determined. The peak area against time for the subjects is presented ([Fig. 4](#f4){ref-type="fig"}). Their average areas under the concentration curves, *AUC* in the plasma after a single oral administration of 40 mL of K-601 was also presented ([Fig. 4](#f4){ref-type="fig"}).

Effect of intestinal flora on the metabolism and biotransformation of K-601
---------------------------------------------------------------------------

This experiment was done to assess the influence of intestinal flora on the metabolism and biotransformation of K-601 shown in [Supplementary Figure S2](#S1){ref-type="supplementary-material"}. Aside the metabolism by the liver, the intestinal microbiota could play an initial metabolic role on drugs before absorption. Using the flora from the human fecal specimen, a total of 28 metabolites were tentatively identified ([Table 4](#t4){ref-type="table"}).

Discussion
==========

Herbal preparations have gained growing popularity worldwide. Because of chemical complexity, little is known about their pharmacokinetics in humans. K-601 is a hospital-prepared herbal formulation extensively used for treatment of influenza in China. In this work, we characterized the chemical constituents in K-601, identified the absorbed compounds and determined their pharmacokinetics in 6 Chinese and African volunteers by UPLC-Q/TOF-MS.

The quality of the K-601 formulation was evaluated by lot-to-lot consistency. Chromatograms from nine batches of the formulation were assessed. The results showed a high consistency among various batches. For the qualitative determination of K-601, we applied the diagnostic-ion screening strategy[@b5][@b21][@b22]. The rationale behind this method is that, since compounds in the formulation belong to one of several families such as flavonoid, glycosides, alkaloid, etc., each one has a characteristic carbon skeleton. Homologous compounds share the same structural units, thus a common fragmentation pathway, specific to that family of compounds. Using the diagnostic fragmentalion screening strategy, 50 compounds were identified in the formulation. Some of these compounds were further confirmed using available reference compounds.

Pharmacochemistry is based on the premise that only the absorbed components of a formulation could exert a therapeutic effect[@b23][@b24][@b25]. This includes both prototype compounds as well as metabolites. The prototype compounds with high and moderate peak abundances were selected for further pharmacokinetic studies. These were determined as berberine, jatrorrhizine, palmatine and magnoflorine. The rest of the prototype compounds identified in the plasma gave low peak abundances per our criteria. Interestingly, alkaloids were present about 100-fold higher than other compounds.

A total of 17 metabolites were identified. The major metabolic pathways of the detected metabolites were glucuronidation, sulfation, methylation, demethylation, and reduction. These pathways can be traced to the two phases of metabolism, phase I and phase II. Phase I metabolism usually converts a parent drug to more polar (water soluble) active metabolites by unmasking or inserting a polar functional group such as −OH, −SH, −NH~2~ etc. Oxidation and hydrolysis constitute some examples of phase I metabolism. Glucuronidation, acetylation and sulphation reactions are examples of phase II metabolism. These 'conjugation reactions' also increase the water solubility of a drug molecule with a polar moiety such as acetate, glucuronide or sulphate.

The pharmacokinetics of the four major prototype compounds were different in the African and Chinese volunteers. The *AUC* values for the African volunteers were higher than that of the Chinese with respect to the three benzylisoquinoline alkaloids (berberine, jatrorrhizine, and palmatine). Magnoflorine, one of the aporphine alkaloids, performed better in the Chinese volunteers than in the Africans. The time taken for these prototype compounds to reach maximum concentration (*T*~*max*~) in the blood was another major difference detected. The *T*~*max*~ for berberine, jatrorrhizine, and palmatine was 4 hours in the African volunteers corresponding to the results in rat model[@b26]. While for the Chinese volunteers, *T*~*max*~ was observed at 1 hour. These results go to proof that racial and structure differences play crucial roles in the pharmacokinetics of drugs, and thus influences dosing. Three possible explanations could be given for the difference: (1) The African volunteers absorb the drug slower and better or metabolize the drug slower than the Chinese volunteers. (2) The drug is poorly absorbed by the Chinese volunteers or they quickly metabolize the drug. (3) Structures may play a vital role in their ability to be absorbed or metabolized.

We investigated the possible role of intestinal microbiota in the biotransformation and metabolism of the components of K-601. This was done using flora from feces of an adult male African. The results of the study revealed after 48 hours of anaerobically incubating K-601 with the intestinal flora, that biotransformation and metabolism took place. These metabolites were found to be from the parent compounds of gallic acid, secologanoside, 4-*O*-caffeoylquinic acid and its isomers, emodin, lotusine, palmatine, berberine and baicalin. The metabolic pathways included hydroxylation, methylation, sulfation, acetylation, demethylation and reduction. These metabolites were found in high, moderate and low concentrations. Metabolites of emodin, lotusine, palmatine, berberine were detected in high concentrations. Glucuronide conjugates were conspicuously missing as metabolites. These might be transformed after liver metabolism. It should be noted that since the intestinal microbiota contains trillions of bacteria, representing species and subspecies[@b27], the environment of these bacteria is not constant. Variable population of intestinal flora may lead to diverse metabolic results depending on the host conditions such as diet, health and even stress[@b28]. Several factors could affect the metabolism of herbal medicines. Due to competitive absorption, metabolism and exposure of different concentrations of the constituents *in vivo* and *in vitro*, the metabolic profiles of K-601 may differ[@b29].

The following are the limitations of this study: (1) The sample size for the study (6 persons) was small and not adequate. This was because we could not get more than the 6 persons to volunteer for the study since the study was conducted in China where the African population is very small. (2) Though the subjects fasted throughout the period of study, six hours might not be adequate to comprehensively determine the pharmacokinetics of the all components.

Methods
=======

Identification of chemical components of K-601
----------------------------------------------

### Sample preparation

In order to comprehensively determine the metabolites of the formulation upon ingestion, the chemical composition was first determined. 1 mL of this herbal product was dissolved in 1 mL of distilled water (purified by Milli-Q system, Millipore, USA). The resultant solution was centrifuged at 13000 rpm for 10 min and then the supernatant was transferred to a sample vial for UPLC-MS analysis.

### UPLC-QTOF/MS analysis

Chromatographic analysis was performed on an Agilent 1290 Series (Agilent Corp., Santa Clara, CA, USA,) UPLC system equipped with a binary pump, micro degasser, an auto sampler and a thermostatically controlled column compartment. Chromatographic separation was carried out at 25 ^o^C on a Zorbax RRHD Eclipse Plus C~18~ column (2.1 × 50 mm, 1.8 μm). The mobile phase consisted of 0.1% formic acid solution (A) and ACN (B) using a gradient elution of 0--5% B at 0--6 min, 5--8% B at 6--15 min, 8--15% B at 15--20 min, 15--20% B at 20--30 min, 20--30% at 30--35 min, 30--35% at 35--45 min, 35--40% at 45--60 min. The flow rate was kept at 0.2 mL/min, and the sample volume injected was set at 5 μL. Detections were carried out by Agilent 6530 Q/TOF mass spectrometer (Agilent Corp., Santa Clara, CA, USA) equipped with an ESI interface. The parameters of operation were as follows: drying gas N~2~ flow rate, 10.0 L/min; temperature, 330 ^o^C; nebulizer, 35 psig; capillary, 3000 V; skimmer, 60 V; OCT RFV, 250 V. Each sample was analyzed in both the positive and negative modes due to the selective sensitivities to different components of the formulation-providing better information for molecular formulae and structural identification. Mass spectra were recorded across the range *m/z* 100--1000 with accurate mass measurements.

Quality Evaluation of K-601
---------------------------

### Sample preparation

The sample preparation was same as stated above (identification).

### UPLC analyses

Chromatographic separation conditions were same as that used for UPLC-QTOF/MS. However, detection was done at the wavelength of 360 nm with DAD detector.

### Data analyses

The chromatographic peaks were introduced into the *Similarity Evaluation System for Chromatographic Fingerprint of Traditional Chinese Medicine* (version 2004A, National Committee of Pharmacopoeia, China).

Effect of intestinal flora on K-601
-----------------------------------

### Human fecal sample preparation

The method used for the preparation of human fecal specimen was according to that already reported[@b30]. Briefly, 3 g of fresh human feces from a healthy male (31 years old, non-smoker, not on any medication especially antibiotics and fasting as of the time of sample collection) was weighed into a beaker. This was then suspended in 30 mL normal saline solution, filtered through a gauze and centrifuged at 13000 rpm for 30 min. The supernatant was filtered with gauze and the resultant filtrate was used as the intestinal flora fraction.

### Biotransformation and metabolism of K-601 by human fecal flora

Three (3) conical flasks containing 30 mL of anaerobic physiological media labelled A, B and C were used. To flask A, was added 1 mL of K-601 and 2 mL of intestinal flora. To flask B was added only 2 mL of intestinal flora while only 1 mL of the K-601 was added to the content of flask C. The contents of these 3 flasks were anaerobically incubated at 37 ^°^C for 48 hours. The mixtures were then extracted 3 times with 50 mL ethyl acetate. The remaining mixtures were re-extracted 3 times with 50 mL *n*-butanol. The combined *n*-butanol extracts were then washed 3 times with water. Both extracts were concentrated in vacuo and then diluted to the desired volume with methanol. The ethyl acetate and *n*-butanol extracted contents were mixed and centrifuged at 13000 rpm for 10 min before injected for analysis.

Pharmacokinetics study
----------------------

### Study subjects

A total of six healthy male volunteers, ages ranging from 22--47 years took part in this study. Three of whom are Africans and three Chinese. All volunteers avoided the intake of alcohol/alcoholic beverages, coffee/beverages containing coffee for at least 12 hours prior to the study. None was also on any medication. All volunteers also fasted for 12 hours prior to the study and throughout the study period.

Blood samples were withdrawn from subjects at the following time intervals, 0 hour (before taking medication and breakfast), 1, 2, 4, and 6 hours after taking the medication. These blood samples were taken by a qualified phlebotomist in the hospital. Each volunteer took 40 mL of same batch of the medication as a single dose. This study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (2013-SRFA-078) and conducted under the guidelines of the Helsinki Declaration and the International Conference on Harmonization-Good Clinical Practices (ICH-GCP). Details of subjects in the pharmacokinetic studies are provided ([Table 5](#t5){ref-type="table"}).

Treatment of plasma samples
---------------------------

All blood samples taken at each time were immediately centrifuged at 13000 rpm for 10 min, and the plasma separated and stored at −80 ^°^C until analysis. Plasma samples were thawed at 37 ^°^C before solid-phase extraction (SPE) treatment for UPLC-QTOF/MS analysis. The sample treatment procedure is schematically presented in [Supplementary Figure S3](#S1){ref-type="supplementary-material"}.

### Pharmacokinetics Analysis

Pharmacokinetic analyses were done using the extracted ion chromatograms (EIC) of the most abundant compounds. The peak areas of derived from the EIC were plotted against time (h).

[Ethical Standards:](#S1){ref-type="supplementary-material"} All participants were required to give a written, informed consent. The studies was approved by the ethical committee and conducted in accordance with the Helsinki Declaration and Good Clinical Practice guidelines of ICH. <http://www.nature.com/srep>
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###### Compounds identified in K-601 heji in positive and negative modes.

  **No.**   ***t*~R~(min)**   **ESI mode**   **Fragment ions, *m/z***                                     **Formula**          **Identity**                                                                                      **Abund. (×10^6^)**    **Peak abundance**   **Source**
  --------- ----------------- -------------- ------------------------------------------------------------ -------------------- ------------------------------------------------------------------------------------------------- --------------------- -------------------- ------------
  1         4.265             −              169.0134, 125.0246                                           C~7~H~6~O~5~         Gallic acid[\*](#t1-fn1){ref-type="fn"}                                                           16.06                         High              RP
  2         6.174             −              331.0670, 271.0433, 211.0235, 169.0139                       C~13~H~16~O~10~      Gallic acid 3-*O*-β-D-glucopyranoside                                                             2.93                         Medium             RP
  3         11.765            −              389.1051, 345.1085, 183.0641, 165.0548                       C~16~H~22~O~11~      Secologanoside                                                                                    16.70                         High              LJ
  4         17.136            −              353.0871, 191.0540                                           C~16~H~18~O~9~       Chlorogenic acid[\*](#t1-fn1){ref-type="fn"}                                                      4.78                         Medium             LJ
  5         17.36             −              179.0331, 135.043                                            C~9~H~8~O~4~         Caffeic acid[\*](#t1-fn1){ref-type="fn"}                                                          3.17                         Medium             LJ
  6         22.593            −              353.0869, 191.0533, 179.0316, 173.0424, 161.0187, 135.0421   C~16~H~18~O~9~       4-*O*-caffeoylquinic acid                                                                         22.43                         High              LJ
  7         22.999            −              353.0863, 191.0531, 179.0316, 173.0324                       C~16~H~18~O~9~       5-*O*-caffeoylquinic acid                                                                         21.06                         High              LJ
  8         24.536            −              357.1197, 195.0671, 151.0761, 125.0251                       C~16~H~22~O~9~       Sweroside                                                                                         9.72                         Medium             LJ
  9         26.053            −              367.1028, 191.0534                                           C~17~H~20~O~9~       Caffeoyl-CH~2~-*O*-quinic acid                                                                    8.36                         Medium             LJ
  10        32.45             −              269.0439, 240.0408, 211.0400                                 C~15~H~10~O~5~       Aloe-emodin[\*](#t1-fn1){ref-type="fn"}                                                           0.21                          Low               RP
  11        33.286            −              609.1475, 301.0325                                           C~27~H~30~O~16~      Rutin[\*](#t1-fn1){ref-type="fn"}                                                                 0.53                          Low               SC
  12        33.455            −              445.0756, 283.0241, 239.0326,                                C~21~H~18~O~11~      Rhein-8-*O*-β-D-glucopyranoside                                                                   0.04                          Low               RP
  13        33.658            −              447.0897, 285.0396                                           C~21~H~20~O~11~      Luteolin-7-*O*-β-D-glucoside                                                                      0.75                          Low               RP
  14        33.692            −              463.0895, 301.0340, 271.0291                                 C~21~H~20~O~12~      Hyperoside                                                                                        0.42                          Low               LJ
  15        33.861            −              461.0737, 285.0339                                           C~21~H~18~O~12~      Scutellarin                                                                                       0.47                          Low               SC
  16        33.937            −              593.1519, 447.0962, 285.0401                                 C~27~H~30~O~15~      Lonicerin[\*](#t1-fn1){ref-type="fn"}                                                             0.52                          Low               LJ
  17        34.756            −              515.1189, 353.0873, 191.0551, 179.0346                       C~25~H~24~O~12~      1,5-*O*-dicaffeoylquinic acid or 4,5-*O*-dicaffeoylquinic acid or 3,5-*O*-dicaffeoylquinic acid   0.05                          Low               LJ
  18        36.809            −              269.0476, 167.0507                                           C~15~H~10~O~5~       Baicalein[\*](#t1-fn1){ref-type="fn"}                                                             0.12                          Low               SC
  19        37.817            −              269.0456, 240.0408, 211.0400, 167.0518                       C~15~H~10~O~5~       Emodin[\*](#t1-fn1){ref-type="fn"}                                                                12.33                         High              RP
  20        38.152            −              269.0452, 225.0539, 197.0564, 183.0448                       C~15~H~10~O~5~       Apeginin                                                                                          0.24                          Low               LJ
  21        38.701            −              253.0488, 225.0556                                           C~15~H~10~O~4~       Chrysophanol                                                                                      0.22                          Low               RP
  22        39.326            −              253.0504, 225.0557                                           C~15~H~10~O~4~       Chrysin                                                                                           0.31                          Low               RP
  23        39.410            −              431.0987, 395.1032, 311.0588, 269.0468                       C~21~H~20~O~10~      Aloe-emodin-8-*O*-glucoside                                                                       0.40                          Low               RP
  24        40.027            −              459.0952, 283.0612, 268.0376                                 C~22~H~20~O~11~      Wogonoside[\*](#t1-fn1){ref-type="fn"}                                                            16.97                         High              SC
  25        40.263            −              283.0605, 268.0363, 240.0372                                 C~16~H~12~O~5~       Physcion                                                                                          0.72                          Low               RP
  26        43.895            −              269.0463, 241.0521, 225.0543                                 C~15~H~10~O~5~       Norwogonin                                                                                        0.26                          Low               SC
  27        45.416            −              313.7373, 229.2099, 211.1348, 171.1012                       C~18~H~34~O~5~       Sanleng acid                                                                                      2.90                         Medium             RP
  28        47.544            −              297.0409, 253.0501, 225.0517                                 C~16~H~10~O~6~       6-Methyl-rhein                                                                                    0.17                          Low               RP
  29        52.055            −              283.0260, 239.0343, 211.0411, 183.0413                       C~15~H~8~O~6~        Rhein[\*](#t1-fn1){ref-type="fn"}                                                                 0.28                          Low               RP
  30        4.076             \+             180.1286, 121.0535                                           C~11~H~18~NO         Candicine                                                                                         4.02                         Medium             PC
  31        20.496            \+             314.1716, 269.1167, 237.0903, 192.1009, 143.0486             C~19~H~23~NO~3~      Lotusine                                                                                          24.34                         High              PC
  32        22.430            \+             342.1687, 192.1007                                           C~20~H~24~NO~4~      Phellodendrine[\*](#t1-fn1){ref-type="fn"}                                                        25.40                         High              SC
  33        23.461            \+             344.1854, 299.1283, 207.0766, 175.0748, 137.0590             C~20~H~26~NO~4~      Tembetarine                                                                                       20.21                         High              PC
  34        23.498            \+             342.1730, 297.1121, 265.0859                                 C~20~H~23~NO~4~      Magnoflorine[\*](#t1-fn1){ref-type="fn"}                                                          25.39                         High              PC
  35        24.120            \+             342.1684, 297.1102, 265.0852                                 C~20~H~23~NO~4~      Tetrahydrojatrorrhizine                                                                           25.32                         High              PC
  36        28.613            \+             356.1853, 311.1271, 279.1016                                 C~21~H~25~NO~4~      Menisperine                                                                                       22.31                         High              PC
  37        30.26             \+             312.1591, 297.1361, 267.1191, 252.1016                       C~19~H~21~NO~3~      Veticuline                                                                                        0.32                          Low               PC
  38        31.966            \+             356.1854, 192.1017                                           C~21~H~25~NO~4~      Tetrahydropalmatine                                                                               24.19                         High              PC
  39        31.975            \+             356.1855, 297.0821, 192.1017, 177.0780, 148.0752             C~21~H~26~NO~4~      N-Methyltetrahydrocolumbamine                                                                     23.19                         High              PC
  40        35.193            \+             338.1377, 322.1072, 308.0908, 294.1118, 280.0951             C~20~H~20~NO~4~      Jatrorrhizine[\*](#t1-fn1){ref-type="fn"}                                                         2.03                         Medium             PC
  41        37.544            \+             352.1534, 336.1228, 322.1074, 308.1277, 294.1121             C~21~H~22~NO~4~      Palmatine[\*](#t1-fn1){ref-type="fn"}                                                             25.38                         High              PC
  42        37.722            \+             336.1233, 334.1071, 306.0764, 292.0968                       C~20~H~18~NO~4~      Berberine[\*](#t1-fn1){ref-type="fn"}                                                             23.26                         High              PC
  43        37.783            \+             445.0772, 271.0608                                           C~21~H~18~O~11~      Baicalin[\*](#t1-fn1){ref-type="fn"}                                                              24.40                         High              SC
  44        38.119            \+             320.0911, 292.0962                                           C~20~H~18~NO~4~      Epiberberine                                                                                      0.06                          Low               PC
  45        38.600            \+             263.0820                                                     C~16~H~10~N~2~O~2~   Indigotin                                                                                         0.25                          Low               II
  46        42.955            \+             437.3389, 409.3480, 366.0660                                 C~26~H~30~O~7~       Obacunone                                                                                         0.12                          Low               PC
  47        44.121            \+             329.2210, 316.0589, 301.0377, 287.0624, 273.0374             C~17~H~14~O~7~       Iristectorigenin A or Iristectorigenin B                                                          1.73                         Medium             LJ
  48        44.121            \+             329.2210, 316.0589, 301.0377, 287.0624, 273.0374             C~17~H~14~O~7~       Iristectorigenin A or Iristectorigenin B                                                          1.73                         Medium             LJ
  49        50.202            \+             453.1858, 425.1962, 367.1909                                 C~26~H~30~O~8~       Obaculactone                                                                                      2.33                         Medium             PC
  50        51.52             \+             285.0760, 270.0522                                           C~16~H~12~O~5~       Wogonin[\*](#t1-fn1){ref-type="fn"}                                                               2.80                         Medium             SC

The relative abundance of the compounds measured by the peak height in the **EIC \> 10.00 × 10**^**6**^, defined as major constituent, thus high level**; (1.00--10.00) × 10**^**6**^, defined as minor constituent, meaning moderate level; **\<1.00 × 10**^**6**^ defined as trace constituent, hence present in low levels.

**PC**: *Phellodendron chinense* Schneid **LJ**: *Lonicera japonica* Thunb **II**: *Isatis indigotica* Fort **SC**: *Scutellaria baicalensis* Geo **RP**: *Rheum palmatum* L.

^\*^Authenticated with reference standards.

###### Prototype compounds identified in the plasma of study subjects.

  **No.**   **t~R~(min)**    **ESI mode**  ***m/z***      **Formula**                                              **Identity**                                            **Abund. (×10^4^)**    **Peak abundance**
  --------- --------------- -------------- ----------- ----------------- ------------------------------------------------------------------------------------------------- --------------------- --------------------
  P1        22.481                \+       342.1692     C~20~H~23~NO~4~                                            Magnoflorine                                            6.52                        Moderate
  P2        24.166                \+       356.1854     C~21~H~25~NO~4~                                         Tetrahydropalmatine                                        0.03                          Low
  P3        35.154                \+       338.1375     C~20~H~20~NO~4~                                            Jatrorrhizine                                           3.53                        Moderate
  P4        36.507                \+       352.1534     C~21~H~22~NO~4~                                              Palmatine                                             12.63                         High
  P5        36.738                \+       336.1229     C~20~H~18~NO~4~                                              Berberine                                             50.35                         High
  P6        11.756                −        389.1058     C~16~H~22~O~11~                                           Secologanoside                                           0.02                          Low
  P7        15.863                −        353.0843     C~16~H~18~O~9~                                           Chlorogenic acid                                          0.03                          Low
  P8        22.539                −        353.0854     C~16~H~18~O~9~                                       4-*O*-caffeoylquinic acid                                     0.04                          Low
  P9        27.035                −        367.1028     C~17~H~20~O~9~                                    Caffeoyl-CH~2~-*O*-quinic acid                                   0.03                          Low
  P10       33.654                −        463.0890     C~21~H~20~O~12~                                             Hyperoside                                             0.05                          Low
  P11       34.787                −        515.1155     C~25~H~24~O~12~   1,5-*O*-dicaffeoylquinic acid or 4,5-*O*-dicaffeoylquinic acid or 3,5-*O*-dicaffeoylquinic acid  0.06                          Low
  P12       36.820                −        269.0439     C~15~H~10~O~5~                                                Emodin                                               0.04                          Low
  P13       40.059                −        459.0915     C~22~H~20~O~11~                                             Wogonoside                                             0.42                          Low
  P14       52.048                −        283.0260      C~15~H~8~O~6~                                                 Rhein                                               0.62                          Low
  P15       47.536                −        297.0411     C~16~H~10~O~6~                                            6-Methyl-rhein                                           0.06                          Low

The relative abundance of the compounds measured by peak height in the **EIC \> 1.00 × 10**^**4**^, defined as major constituent, thus high-level**: (0.10--1.00) × 10**^**4**^ as minor constituent, meaning moderate level: **\<0.10 × 10**^**4**^ as trace constituent, thus low-level.

###### Metabolites identified in human plasma after administration of K-601.

  **No.**   ***t*~R~(min)**    **ESI mode**  ***m/z***      **Metabolic pathway**       **Formula**     **Parent compound**  **Abund. (×10^4^)**    **Peak abundance**
  --------- ----------------- -------------- ----------- --------------------------- ----------------- --------------------- --------------------- --------------------
  M1        7.600                   −        250.9807        Reduction+Sulfation       C~7~H~8~O~8~S        Gallic acid      0.02                          Low
  M2        9.927                   −        183.0284            Methylation           C~8~H~8~O~5~         Gallic acid      0.21                        Moderate
  M3        9.229                   −        155.0713             Reduction            C~7~H~6~O~4~       Secologanoside     0.04                          Low
  M4        20.380                  −        393.1383             Reduction           C~16~H~24~O~11~     Secologanoside     0.03                          Low
  M5        6.999                   −        407.1549       Reduction+methylation     C~17~H~26~O~11~     Secologanoside     0.03                          Low
  M6        31.328                  −        255.0639             Reduction           C~15~H~10~O~4~          Emodin         0.05                          Low
  M7        34.458                  −        445.0760          Glucuronidation        C~21~H~18~O~11~         Emodin         0.50                        Moderate
  M8        26.855                  −        447.0938     Reduction+glucuronidation   C~21~H~20~O~11~         Emodin         0.03                          Low
  M9        38.918                  −        283.0604            Methylation          C~16~H~12~O~5~          Emodin         0.03                          Low
  M10       43.378                  −        255.0286           Demethylation          C~14~H~8~O~5~          Emodin         0.02                          Low
  M11       31.429                  \+       447.0923          Glucuronidation        C~21~H~18~O~11~         Emodin         0.50                        Moderate
  M12       9.533                   \+       358.2074       Reduction+methylation     C~21~H~28~NO~4~     Phellodendrine     2.00                          High
  M13       32.037                  \+       352.1536       Reduction+methylation     C~21~H~22~NO~4~        Berberine       1.50                          High
  M14       23.522                  \+       463.0863           Hydroxylation         C~21~H~18~O~12~        Baicalin        0.05                          Low
  M15       34.470                  \+       431.0965             Reduction           C~21~H~18~O~10~        Baicalin        0.06                          Low
  M16       26.361                  \+       449.1069             Reduction           C~21~H~20~O~11~        Baicalin        0.03                          Low
  M17       35.281                  \+       461.1084            Methylation          C~22~H~20~O~11~        Baicalin        1.20                          High

The relative abundance of the compounds measured by peak height in the **EIC \> 1.00 × 10**^**4**^, defined as major constituent, thus high-level**: (0.10--1.00) × 10**^**4**^ as minor constituent, meaning moderate level: **\<0.10 × 10**^**4**^ as trace constituent, thus low-level.

###### Metabolites identified in the human intestinal transformation of K-601.

  --------- ----------------- -------------- ----------- --------------------------- ----------------- --------------------------- --------------------- --------------------
  **No.**    ***t*~R~(min)**   **ESI mode**   ***m/z***     **Metabolic pathway**       **Formula**        **Parent compound**      **Abund. (×10^4^)**   **Peak abundance**
  T1              2.187             \+        185.0565          Hydroxylation          C~7~H~6~O~6~            Gallic acid                 0.05                  Low
  T2              1.680             \+        199.0260    Hydroxylation+methylation    C~8~H~8~O~6~            Gallic acid                 0.10                  Low
  T3              5.633             \+        153.0203            Reduction            C~7~H~6~O~4~            Gallic acid                 1.80                  High
  T4              7.600             \+        211.0247            Sulfation            C~9~H~8~O~6~            Gallic acid                 0.13                  Low
  T5              1.274             \+        405.1042          Hydroxylation         C~16~H~22~O~12~        Secologanoside                0.04                  Low
  T6             22.458             \+        373.1153         2×Hydroxylation        C~16~H~22~O~13~        Secologanoside                0.03                  Low
  T7             21.849             \+        431.1184           Acetylation          C~18~H~24~O~12~        Secologanoside                0.02                  Low
  T8             21.951             \+        403.1252           Methylation          C~17~H~24~O~11~        Secologanoside                4.00                  High
  T9             23.268             \+        369.1185      Reduction+methylation     C~17~H~22~O~9~    4-*O*-caffeoylquinic acid          0.02                  Low
  T10            23.573             \+        367.1035           Methylation          C~17~H~20~O~9~    4-*O*-caffeoylquinic acid          6.00                  High
  T11            24.282             \+        367.1039           Methylation          C~17~H~20~O~9~    5-*O*-caffeoylquinic acid          5.50                  High
  T12            36.343             \+        285.0408          Hydroxylation         C~15~H~10~O~6~             Emodin                    3.00                  High
  T13            42.323             \+        299.0562    Hydroxylation+methylation   C~16~H~12~O~6~             Emodin                    5.00                  High
  T14            51.952             \+        253.0306            Reduction           C~15~H~10~O~4~             Emodin                    15.00                 High
  T15            38.269             \+        301.0356         2×Hydroxylation        C~15~H~10~O~7~             Emodin                    4.00                  High
  T16            51.040             \+        283.0617           Methylation          C~16~H~12~O~5~             Emodin                    30.00                 High
  T17            24.078             \+        344.1851    Hydroxylation+methylation   C~20~H~25~NO~4~           Lotusine                   7.50                  High
  T18            28.944             \+        356.1849           Acetylation          C~21~H~25~NO~4~           Lotusine                   17.00                 High
  T19            21.949             \+        328.1914           Methylation          C~20~H~25~NO~3~           Lotusine                   4.00                  High
  T20            23.368             \+        300.1583          Demethylation         C~18~H~21~NO~3~           Lotusine                   2.00                  High
  T21            44.760             \+        368.1867      Reduction+methylation     C~22~H~26~NO~4~           Palmatine                  1.50                  High
  T22            35.432             \+        338.1386          Demethylation         C~20~H~20~NO~4~           Palmatine                  10.00                 High
  T23            33.303             \+        352.1183          Hydroxylation         C~20~H~18~NO~5~           Berberine                  0.70                Moderate
  T24            20.124             \+        368.1157         2×Hydroxylation        C~20~H~18~NO~6~           Berberine                  3.00                  High
  T25            35.534             \+        338.1386            Reduction           C~20~H~20~NO~4~           Berberine                  9.00                  High
  T26            37.055             \+        352.1546      Reduction+methylation     C~21~H~22~NO~4~           Berberine                  10.00                 High
  T27            35.533             −         475.0877    Hydroxylation+methylation   C~22~H~20~O~12~           Baicalin                   0.02                  Low
  T28            36.141             −         429.0832            Reduction           C~21~H~18~O~10~           Baicalin                   1.00                Moderate
  --------- ----------------- -------------- ----------- --------------------------- ----------------- --------------------------- --------------------- --------------------

The relative abundance of the compounds measured by peak height in the **EIC \> 1.00 × 10**^**4**^, defined as major constituent, thus high-level**: (0.10--1.00) × 10**^**4**^ as minor constituent, meaning moderate level: **\<0.10 × 10**^**4**^ as trace constituent, thus low-level.

###### Details of subjects in the pharmacokinetic studies.

  **Age**   **BMI(kg/m^2^)**    **Country of origin**
  --------- ------------------ -----------------------
  31        25.1                        Ghana
  31        25.7                       Zambia
  47        24.8                       Nigeria
  22        23.7                        China
  23        21.9                        China
  23        20.3                        China

[^1]: These authors contributed equally to this work.
